PRINCETON, N.J. & BANGALORE, India--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.
Bristol-Myers Squibb and Syngene International Extend Research Collaboration | BMS Newsroom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.